ASCO Breakthrough 2026
Envafolimab Regimen Improves Pathologic Complete Response in MSS Locally Advanced Rectal Cancer
Adding the subcutaneous PD-L1 blocker envafolimab to short-course radiotherapy and CAPEOX (capecitabine and oxaliplatin) improved pathologic complete response (pCR) without a clear safety or surgical ...
cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions
A blood-based assay combining cell-free DNA (cfDNA) fragmentomics with droplet digital PCR–based methylation analysis improved detection of early-stage colorectal cancer (CRC) and precancerous lesions...
Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced, Refractory Malignancies
Our data on a triplet combination of chemotherapy, immune checkpoint inhibitors, and targeted therapy (ICTriplex) in advanced and refractory malignancies were presented in June at the 2026 ASCO Break...
Rezatapopt Shows Activity in TP53 Y220C–Mutated Advanced Ovarian Cancer
Single-agent rezatapopt produced “very deep and durable responses” in heavily pretreated patients with TP53 Y220C–mutated advanced ovarian cancer, according to updated results from the pivotal phase I...
HER2-Targeted Regimen Yields High Pathologic Complete Response Rate in Locally Advanced Breast Cancer
A human epidermal growth factor receptor 2 (HER2)–targeted regimen achieved high pathologic complete response rates before surgery in patients with locally advanced HER2-positive breast cancer, accord...
Neoadjuvant Inetetamab Plus Pyrotinib Evaluated in HER2-Positive Locally Advanced Breast Cancer in China
Neoadjuvant treatment with the HER2-targeted monoclonal antibody inetetamab in combination with the irreversible pan-HER tyrosine kinase inhibitor pyrotinib (inhibits HER1, HER2, HER4) and chemotherap...
Palliative Care Integrated at Diagnosis Improves QOL for Patients With Breast Cancer in India
Early integration of palliative, or supportive, care at the time of breast cancer diagnosis improved quality of life more than on-demand palliative care in a randomized trial of patients in India. The...
Chinese Study of HER2-Targeted Combination in Neoadjuvant Therapy for Locally Advanced Breast Cancer
A HER2-targeted regimen produced high pathologic complete response rates before surgery in patients with locally advanced HER2-positive breast cancer, according to results from a single-arm phase II n...
GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
A large retrospective cohort study found that GLP-1 receptor agonist use was associated with significantly lower 5-year rates of colorectal cancer among patients with inflammatory bowel disease (IBD)....
Subgroup Analysis of Inavolisib Regimen in Asian Patients With Advanced Breast Cancer
Treatment with the PI3K inhibitor inavolisib in combination with palbociclib and fulvestrant produced substantial clinical benefits in Asian patients with PIK3CA-mutated, hormone receptor–positive (HR...
Multi-Cancer Early Detection Test Evaluated in Real-World Asian Cohort
A large real-world study conducted across six Asian countries suggests that a blood-based multi-cancer early detection (MCED) test may accurately identify multiple cancer types in routine clinical pra...
